Will availability of inhaled human insulin (Exubera(®)) improve management of type 2 diabetes? The design of the Real World trial

BACKGROUND: Common deterrents to insulin therapy for both physicians and patients are the complexity and burden of daily injections. In January 2006, the first inhaled human insulin (INH, Exubera(® )(insulinhuman [rDNA origin])InhalationPowder) was approved for use in adult patients with type 1 diab...

Descripción completa

Detalles Bibliográficos
Autores principales: Freemantle, Nick, Strack, Thomas R
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2006
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1564148/
https://www.ncbi.nlm.nih.gov/pubmed/16901335
http://dx.doi.org/10.1186/1745-6215-7-25

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1564148/
https://www.ncbi.nlm.nih.gov/pubmed/16901335
http://dx.doi.org/10.1186/1745-6215-7-25

Ejemplares similares